The challenge

Oncology teams must navigate fragmented documentation, payer requirements, authorization review, and manual follow-up. The problem extends beyond form filling: it depends on clinical evidence, responsibilities, workflow state, and safe human decisions.

My responsibilities

As founder, CEO, and NSF principal investigator, I defined research and product priorities, owned the roadmap, translated stakeholder findings into requirements, guided contributors, and conducted analytical research.

Approach

  • Conducted structured healthcare stakeholder discovery and translated recurring workflow problems into product priorities.
  • Defined concepts for clinical evidence readiness, payer-policy evaluation, denial-risk prediction, review controls, and traceable documentation.
  • Developed requirements for human oversight, provenance, uncertainty, role-based access, and auditability.
  • Established research objectives, validation criteria, and prospective pilot measurement plans.

Evidence and outcomes

Directed an NSF SBIR Phase I award of $304,935. The retrospective research program covered 24,167 oncology patients and 200,513 authorization case records. Findings informed the product roadmap and a program of further evaluation.

Evidence boundary: Research performance, workflow simulations, and development prototypes are not equivalent to validated clinical deployment or realized efficiency gains.

Why it matters

The project illustrates how careful clinical discovery and scientific evaluation can produce testable product requirements and guide technology investment without overstating implementation readiness.